Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates

Mikyung Yu,June Qin,Xiumin Liu,Diane Ramsden,Brian Williams,Ivan Zlatev,Dale Guenther,Shigeo Matsuda,Roxanne Tymon,Justin Darcy,Catrina Wong,Jamie Tsung,Peter Zawaneh,Saeho Chong,Christopher S Theile,Nathan Taneja,Arlin Rogers,Ju Liu,Elena Castellanos-Rizaldos,Sarah Bond,Kawai So,Jason Denoncourt,Adam Castoreno,Muthiah Manoharan,Jing-Tao Wu,Kevin Fitzgerald,Martin A Maier,Vasant Jadhav,Jayaprakash K Nair

DOI: https://doi.org/10.1093/nar/gkae350

IF: 14.9

2024-05-16

Nucleic Acids Research

Abstract:Oral delivery is the most widely used and convenient route of administration of medicine. However, oral administration of hydrophilic macromolecules is commonly limited by low intestinal permeability and pre-systemic degradation in the gastrointestinal (GI) tract. Overcoming some of these challenges allowed emergence of oral dosage forms of peptide-based drugs in clinical settings. Antisense oligonucleotides (ASOs) have also been investigated for oral administration but despite the recent progress, the bioavailability remains low. Given the advancement with highly potent and durable trivalent N -acetylgalactosamine (GalNAc)-conjugated small interfering RNAs (siRNAs) via subcutaneous (s.c.) injection, we explored their activities after oral administration. We report robust RNA interference (RNAi) activity of orally administrated GalNAc–siRNAs co-formulated with permeation enhancers (PEs) in rodents and non-human primates (NHPs). The relative bioavailability calculated from NHP liver exposure was <2.0% despite minimal enzymatic degradation in the GI. To investigate the impact of oligonucleotide size on oral delivery, highly specific GalNAc-conjugated single-stranded oligonucleotides known as REVERSIRs with different lengths were employed and their activities for reversal of RNAi effect were monitored. Our data suggests that intestinal permeability is highly influenced by the size of oligonucleotides. Further improvements in the potency of siRNA and PE could make oral delivery of GalNAc–siRNAs as a practical solution.

biochemistry & molecular biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the effectiveness and feasibility of orally delivering GalNAc - conjugated small interfering RNAs (siRNAs) in rodents and non - human primates. Specifically, the research focuses on the following aspects:

1. **Improving oral bioavailability**: Since the oral administration route has problems of low intestinal permeability and pre - systemic degradation for hydrophilic macromolecular drugs (such as siRNAs), the research aims to improve the oral bioavailability of GalNAc - conjugated siRNAs by using permeation enhancers (PEs).

2. **Evaluating the effects of different permeation enhancers**: Multiple permeation enhancers were tested in the study to determine which combinations might be suitable for the oral delivery of siRNAs. The results showed that using sodium caprate (C10) as a permeation enhancer enabled the oral absorption of GalNAc - conjugated siRNAs, but the overall bioavailability was still low.

3. **Investigating the influence of oligonucleotide size on oral delivery**: To further understand the mechanisms affecting bioavailability, the study also examined the absorption of GalNAc - conjugated single - stranded oligonucleotides (REVERSIRs) of different lengths after oral administration. The results indicated that longer REVERSIR molecules required a higher oral dose to achieve the same effect as subcutaneous injection, suggesting that low intestinal permeability is a key factor affecting the efficiency of oral delivery.

4. **Verifying ASGPR - mediated liver uptake**: By comparing the responses of wild - type (WT) and ASGPR - knockout (KO) mice, the study confirmed that the oral delivery of GalNAc - conjugated siRNAs depends on ASGPR - mediated liver uptake.

In summary, the main objective of this paper is to explore and optimize the oral delivery methods of GalNAc - conjugated siRNAs, with the hope of developing more convenient and effective treatment means in the future.